tiprankstipranks
Albemarle Corporation (ALB)
NYSE:ALB
Want to see ALB full AI Analyst Report?

Albemarle (ALB) AI Stock Analysis

6,642 Followers

Top Page

ALB

Albemarle

(NYSE:ALB)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
$125.00
▲(8.84% Upside)
Action:Reiterated
Date:08/06/26
ALB scores moderately, driven primarily by improving fundamentals (debt reduction and a sharp rebound in operating/free cash flow) and a strong, upbeat earnings update with maintained/raised outlook elements. Offsetting these positives are clearly bearish technicals (below key moving averages with negative MACD) and valuation uncertainty given the negative P/E tied to a still-volatile earnings cycle.
Positive Factors
Cash generation
A sustained rebound in operating and free cash flow provides durable liquidity to fund brownfield growth, pay down debt, and support disciplined capital allocation. Over the next 2–6 months stronger cash conversion reduces refinancing risk and increases optionality for strategic investment or buybacks.
Negative Factors
Volatile earnings & low returns
Cyclical swings and low ROIC indicate the asset base currently delivers weak returns versus capital employed. If lithium pricing or demand softens, earnings and cash flow could quickly reverse, limiting sustainable shareholder returns over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
A sustained rebound in operating and free cash flow provides durable liquidity to fund brownfield growth, pay down debt, and support disciplined capital allocation. Over the next 2–6 months stronger cash conversion reduces refinancing risk and increases optionality for strategic investment or buybacks.
Read all positive factors

Albemarle Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating potential shifts in strategic focus or market demand.
Chart InsightsAlbemarle restructured reporting in 2022–23—what used to show as “Lithium” is now reflected largely in Energy Storage with Specialized subsegments (Specialties, Ketjen). Energy Storage has become the revenue engine but has pulled back from 2023 peaks as pricing normalized, even as 2025 volumes and EBITDA improved. Specialties show margin pressure while Ketjen’s turnaround is driving discretionary proceeds; management’s hefty cost cuts and Kemerton idling are margin-protective, but near‑term cash/earnings remain sensitive to lithium pricing and working-capital timing.
Data provided by:The Fly

Albemarle (ALB) vs. SPDR S&P 500 ETF (SPY)

Albemarle Business Overview & Revenue Model

Company Description
Albemarle Corporation (ALB) is a global specialty chemicals company best known as a major producer of lithium products used in rechargeable batteries, serving electric vehicle and energy storage markets. The company operates primarily through its ...
How the Company Makes Money
Albemarle makes money primarily by producing and selling specialty chemical products, with revenue dominated by lithium-related sales. (1) Energy Storage (Lithium): Albemarle generates revenue by selling lithium compounds—most notably lithium hydr...

Albemarle Earnings Call Summary

Earnings Call Date:Aug 05, 2026
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Positive
The call conveyed a strong operational and financial quarter highlighted by robust top‑line growth (net sales +31%), outsized EBITDA expansion (+155%), exceptional cash generation (Q2 cash from operations $710M and $638M FCF) and meaningful cost/productivity gains. Management raised Specialties outlook, advanced DLE pilot results (>90% recoveries) and signaled disciplined capital allocation with attractive brownfield growth options. Offsetting risks include a June fire at Greenbushes (CGP3) that delayed some volume, tight industry inventories and spodumene supply constraints, supply chain impacts from Middle East disruptions (estimated $70–$90M effect), and near‑term margin sensitivity from spodumene price timing. Overall, the positive operational execution, strong cash flow and upgraded outlooks outweigh the near‑term operational and market headwinds.
Positive Updates
Strong Revenue and EBITDA Growth
Second quarter net sales of $1.7 billion, up 31% year‑over‑year; adjusted EBITDA of $858 million, up 155% year‑over‑year; enterprise adjusted EBITDA margin expanded to 49%.
Negative Updates
CGP3 Plant Fire and Volume Impact
Fire at Greenbushes CGP3 on June 9 reduced expected energy storage sales volume; full run rate for CGP3 now assumed in Q1 2027 (slip versus prior internal expectations) and contributed to lower expected Energy Storage volumes for 2026.
Read all updates
Q2-2026 Updates
Negative
Strong Revenue and EBITDA Growth
Second quarter net sales of $1.7 billion, up 31% year‑over‑year; adjusted EBITDA of $858 million, up 155% year‑over‑year; enterprise adjusted EBITDA margin expanded to 49%.
Read all positive updates
Company Guidance
Management said it is maintaining 2026 outlook ranges but expects to land toward the high end of the $20/kg LCE scenario, reflecting Q2 results of $1.7B net sales, $858M adjusted EBITDA (49% enterprise EBITDA margin), $710M cash from operations (>80% operating cash conversion) and $638M free cash flow (net income $480M, EPS $3.52). Key guidance metrics: Energy Storage full‑year sales volumes now expected at 225k–235k t LCE (Q2 = 65k t, avg realized price ≈ $20/kg; Q3 expected sequentially lower), Specialties raised to $1.4–1.6B sales and $275–325M adjusted EBITDA, cost/productivity savings on track to the high end of the $100–150M target (≈$100M run‑rate YTD), reduced capex, and a ~$70–90M estimated unmitigated Middle East supply‑chain impact; CGP3 restarted Aug 1 with full run rate assumed Q1 2027.

Albemarle Financial Statement Overview

Summary
Financials show a cyclical recovery: TTM 2026 revenue improved (~+7.5%) and profitability returned to modestly positive (net margin ~3.1%) after 2024–2025 losses. Balance sheet flexibility is a key positive with debt reduced to ~$2.0B and low debt/equity (~0.18). Cash flow rebounded strongly (TTM 2026 OCF ~$2.15B; FCF ~$1.59B), but earnings and cash-flow consistency remain volatile versus 2022–2023 peak conditions and returns on capital are still low (~1.8%).
Income Statement
54
Neutral
Balance Sheet
66
Positive
Cash Flow
61
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.91B5.14B5.38B9.62B7.32B3.33B
Gross Profit1.41B671.62M60.24M1.20B3.09B1.01B
EBITDA931.69M559.90M-291.83M2.65B3.63B544.86M
Net Income224.18M-510.63M-1.18B1.57B2.69B123.67M
Balance Sheet
Total Assets15.91B16.37B16.61B18.27B15.46B10.97B
Cash, Cash Equivalents and Short-Term Investments1.63B1.62B1.19B889.90M1.50B439.27M
Total Debt1.99B3.30B3.62B4.28B3.32B2.52B
Total Liabilities5.41B6.59B6.41B8.61B7.27B5.17B
Stockholders Equity10.28B9.53B9.96B9.41B7.98B5.63B
Cash Flow
Free Cash Flow1.59B692.47M-992.65M-827.96M646.20M-609.41M
Operating Cash Flow2.15B1.28B687.88M1.33B1.91B344.26M
Investing Cash Flow671.86M-146.01M-1.58B-2.56B-1.42B-666.59M
Financing Cash Flow-3.53B-834.19M1.24B623.91M611.89M50.21M

Albemarle Risk Analysis

Albemarle disclosed 48 risk factors in its most recent earnings report. Albemarle reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Albemarle Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$8.00B18.077.42%4.91%-4.30%-46.24%
64
Neutral
$9.32B-16.43-10.34%-1.57%-183.83%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
61
Neutral
$20.04B-21.86-3.79%6.83%-11.13%-245.92%
60
Neutral
$13.87B-34.60-2.35%1.41%7.87%69.44%
56
Neutral
$18.31B23.4814.69%1.48%18.36%35.24%
48
Neutral
$9.03B-5.53-13.93%2.87%-8.63%-524.43%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALB
Albemarle
125.42
56.30
81.44%
EMN
Eastman Chemical
73.50
15.14
25.94%
LYB
LyondellBasell
61.44
14.87
31.93%
SQM
Sociedad Quimica Y Minera SA
72.45
34.06
88.74%
WLK
Westlake Corporation
77.47
-2.48
-3.11%
AVTR
Avantor
13.18
1.80
15.82%

Albemarle Corporate Events

Business Operations and StrategyExecutive/Board Changes
Albemarle Adds Independent Director to Strengthen Governance
Positive
Jul 23, 2026
On July 21, 2026, Albemarle’s board appointed Eduardo De Salles Bartolomeo as an independent director and member of its Audit Finance and Safety, Sustainability, Operations Capital committees. The former Vale S.A. chief executive brings mo...
Executive/Board Changes
Albemarle Names CFO Interim Principal Accounting Officer
Neutral
Jun 5, 2026
Albemarle Corporation reported that former Chief Accounting Officer Donald J. LaBauve Jr. retired on June 1, 2026, triggering an interim leadership change in its finance organization. Effective June 2, 2026, Executive Vice President and Chief Fina...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Albemarle Shareholders Approve Board, Pay and Incentive Plan
Positive
May 8, 2026
At its annual meeting on May 5, 2026, Albemarle shareholders elected the full slate of board nominees to serve until the 2027 meeting and approved, on an advisory basis, the company’s executive compensation program. Investors also ratified P...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2026